AstraZeneca Inks Over $2B Agreement For Cell Therapies Targeting Diabetes
Portfolio Pulse from Vandana Singh
AstraZeneca has signed an agreement with Quell Therapeutics to develop T-regulator cell therapies for Type 1 Diabetes and Inflammatory Bowel Disease. Quell will receive $85 million upfront and is eligible for over $2 billion in development and commercialization milestones, plus tiered royalties.
June 09, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's partnership with Quell Therapeutics could lead to new treatments for Type 1 Diabetes and Inflammatory Bowel Disease, potentially boosting its revenue.
AstraZeneca's collaboration with Quell Therapeutics has the potential to develop new treatments for Type 1 Diabetes and Inflammatory Bowel Disease. If successful, this could lead to increased revenue for AstraZeneca, positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100